LATE-BREAKING ORAL PRESENTATIONS  by unknown
Purpose/Objective(s): There is an unmet medical need for new systemic
therapies active in NSCLC patients after failure of chemotherapy and
reversible EGFR tyrosine kinase inhibitors (TKIs), erlotinib (E) or gefitinib
(G). Afatinib (A), is an irreversible TKI of EGFR & HER2 with preclinical
activity against EGFR T790M, a common mechanism of resistance in this
setting.
Materials/Methods: 585 adenocarcinoma patients [stage IIIB/IV, PS 0-2,
1-2 prior chemotherapies, progressed after 12 wks of E or G] were
randomized double-blind 2:1 to BSC  either oral A 50 mg qd or placebo
(P). The primary endpoint was OS (90% power to detect a 0.70 HR) with
secondary endpoints that included PFS, objective response rate (ORR), and
disease control rate (DCR).
Results: Patient characteristics [median age (58), women (60%), East Asian
(58%), PS 0-1 (92%)] were balanced across both arms. Successful clinical
enrichment for patients likely to have EGFR mutations was indicated by:
81% of patients with  24 wks of prior E/G and 45% with CR/PR on prior
E/G. At primary analysis (358 events), median OS was 10.8 mos with
BSC  A vs 12.0 mos with BSC  P, HR  1.08 (95% CI 0.86-1.35).
However, treatment with A lead to significant improvement in key secondary
efficacy endpoints: [1] PFS by independent review (3-fold increase in median
PFS from 1.1 to 3.3 mos, HR  0.38, P 0.0001, robust across all
preplanned subgroups); [2] confirmed DCR at 8 wks (58% vs 19%, P 
0.0001); & [3] confirmed ORR (11% vs 0.5% and 7.4% vs 0.5% by
investigator & independent analyses, P  0.01). Median PFS was improved
from 0.97 to 3.7 mos (HR 0.23, P  0.001) in the 263 pts who had CR/PR
to prior E/G. In the 214 patients with clinical benefit on prior E/G (CR/PR or
SD with treatment duration  6 months) AND short interval after prior E/G
and randomization ( 4 wks and no intervening chemotherapy), PFS
improvement for afatinib was as good if not better than the whole study
population: Median PFS of 4.5 mos for afatinib vs. 1.0 mos for placebo.
Since PFS in the placebo arm was very short and OS was long, possible
confounding effects of subsequent treatment on OS are being examined and
will be presented. Diarrhea (87% all grades; 17% gr 3) and rash/acne (78%
all gr; 14% gr 3) were the two most common side effects of A and effectively
managed by supportive care and dose modification.
Conclusions: In this phase III trial, the addition of afatinib to BSC did not
improve OS. Afatinib significantly improved PFS and was associated with a
higher ORR & DCR. Subgroup analysis suggests that the PFS benefit is
higher in patients likely to have EGFR mutations.
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A Phase II Trial of Sequential Versus Concurrent Chemother-
apy and Radiotherapy Using an Accelerated Hypofractionated
Radiation Schedule in Stage III NSCLC
J. Maguire1, R. McMenemin2, N. O’Rourke3, C. Peedell4, M. Snee5, S.
McNee3, V. Kelly1, 1Liverpool Heart and Chest Hospital, Liverpool, United
Kingdom, 2Northern Centre for Cancer Care, Newcastle, United Kingdom,
3The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom,
4James Cook University hospital, Middlesbrough, United Kingdom, 5St
James University Hospital, Leeds, United Kingdom
Purpose/Objective(s): Local tumour control and recurrence is a major
problem in the management of inoperable stage III NSCLC. A strategy to
avoid the detrimental effects of accelerated repopulation - administration of
a radical radiotherapy dose within a period of 28 days - might improve local
control rates and hence survival for this group of patients. To test this
hypothesis, we have conducted a randomised phase II trial in which patients
received a radiation dose of 55Gy in 20 fractions in four weeks, given either
sequentially after four cycles of cisplatinum and vinorelbine or concurrently
with the same chemotherapy.
Materials/Methods: 130 patients were randomised to receive 55Gy (pre-
scribed at the ICRU reference point) in 20 fractions over 4 weeks, with 4
cycles of cisplatinum and vinorelbine given either prior to RT or starting
concurrently with the first fraction of radiation. Trial entry required; patho-
logically confirmed stage III NSCLC judged inoperable by a thoracic
surgeon, and treatable within a radical RT volume with v20  30% and12
cms oesophagus in PTV; PS 0 or 1, FEV1  1L and TLCO  50%. The
protocol did not exclude patients with weight loss or N3 disease, and there
was no upwards age limit. Treatment was with either 3D conformal RT or 4D
(one centre). The required GTV - PTV margin was 1.5 cm for conformal and
1cm for 4D planning. Median age was 62 (range 39 - 77); 61% were male;
histology was 64% squamous, 27% adenoca; 52% were PS 0; 44% had IIIA
and 56% had IIIB disease. Patient characteristics were well balanced be-
tween the two arms.
Results: 67 patients received concurrent treatment and 60 sequential. This
report is at a median follow up of 25 months. The median number of
chemotherapy cycles was 3 in the concurrent arm (con) and four in the
sequential arm (seq). 53% vs 60% of patients had chemotherapy dose delays.
Incidence of Serious Adverse Events was 46% vs 47%. There were 43 grade
3 or 4 toxicities (29% vs 38%) - 15 were grade 4 (7 con, 8 seq). Six con
patients and one seq suffered CTC grade 3 oesophagitis. Grade 4 oesoph-
agitis did not occur. 49.3% of patients receiving concurrent treatment and
64.4% of sequential patients have died. Median survival was 27.6 months for
concurrent (projected) and 18.8 months for sequential treatment. Two year
survival is 54% for patients receiving 55Gy in 20 fractions with concurrent
cisplatinum and vinorelbine.
Conclusion: This is the first randomised trial in stage III NSCLC to achieve
a two year survival rate in excess of 50%. A strategy to minimise the effects
of accelerated repopulation using accelerated hypofractionated radiotherapy
with chemotherapy is effective for patients with stage III NSCLC.
Author Disclosure Block: J. Maguire: D. Speaker’s Bureau/Honoraria;
Pierre Fabre. F. Consulting/Advisory Board; Eli Lilly. R. McMenemin: D.
Speaker’s Bureau/Honoraria; Pfizer. F. Consulting/Advisory Board; Bayer.
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Use of a Continuous EGFR IHC Scoring Method Reveals Asso-
ciation between Tumor Response and EGFR Expression Levels
for Patients Receiving Cetuximab  CT versus CT Alone in the
Phase III Trial FLEX in Advanced NSCLC
K. O’Byrne1, W. E. E. Eberhardt2, S. Störkel3, K. Schumacher4, S. Heeger4,
C. Stroh4, I. Celik4, A. von Heydebreck4, R. Pirker5, 1St. James’s Hospital,
Dublin, Ireland, 2University Hospital Essen, University Duisberg-Essen,
Essen, Germany, 3Institute of Pathology der UWH, Helios Klinikum Wup-
pertal, Wuppertal, Germany, 4Merck KGaA, Darmstadt, Germany, 5Medical
University of Vienna, Vienna, Austria
Purpose/Objective(s): The FLEX phase III trial in advanced NSCLC
showed a statistically significant overall survival benefit for patients receiv-
ing cetuximab  CT versus CT alone (Pirker R et al. Lancet 2009, 373,
1525). Objective response rates were 36.4% in the cetuximab  CT arm
versus 29.2% in the CT alone arm. The objective of this study was to
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investigate the association of tumor EGFR expression levels with response
rates in FLEX.
Materials/Methods: The proportion of EGFR-positive cells and membrane
staining intensity for EGFR expression were prospectively collected and
analyzed via a blinded review by centralized pathologists for 1121 patients.
The FDA approved Dako EGFR pharmDx kit was used for immunohisto-
chemical detection of EGFR expression. EGFR expression levels were
determined via a continuous EGFR IHC scoring system ranging from 0–300
based on a composite score consisting of proportion of positive cells and
membrane staining intensity. The association of the obtained EGFR IHC
scores with objective response rates was analyzed.
Results: The EGFR IHC scores were approximately uniformly distributed
across the range from 0-300. No difference between treatment arms was
seen. An increasing benefit for tumor response in favour for cetuximab CT
compared to CT alone was observed above an EGFR IHC score of 150.
Above a cut-off of 200, a clear benefit of cetuximab  CT compared to CT
alone was seen. Patients with EGFR IHC score 200 had similar response
rates in both arms, 32.6% in the cetuximab  CT arm vs 29.6% in the CT
alone arm. In contrast, for patients with EGFR IHC score  200, the
response rate was increased to 44.4% in the cetuximab  CT arm versus
28.1% in the CT alone arm. A treatment interaction test assessing the
difference of the response rates between the two groups defined by the EGFR
IHC score with the cut-off of 200 yielded a p-value of 0.040.
Conclusion: A positive association between increasing EGFR expression
levels and tumor response for patients receiving cetuximab  CT versus CT
alone was observed in the FLEX phase III study. This indicates a potential
predictive value of EGFR expression levels for cetuximab efficacy in
NSCLC.
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LBOA2
Randomized Study of Pralatrexate vs Erlotinib in 2nd- and
3rd-Line Advanced Non-Small Cell Lung Cancer (NSCLC):
Results in Subgroups and Factors Affecting Outcome
K. Kelly1, C. G. Azzoli2, G. Weems3, T. Koutsoukos3, P. Zatloukal4, J. D.
Patel5, 1University of Kansas Medical Center, Kansas City, KS, 2Memorial
Sloan-Kettering Cancer Center, New York, NY, 3Allos Therapeutics, Inc.,
Westminster, CO, 4Third Faculty of Medicine, Charles University, Faculty
Hospital Bulovka and Postgraduate Medical Institute, Prague, Czech Re-
public, 5Northwestern University, Chicago, IL
Purpose/Objective(s): PDX-012 is a randomized, phase 2b study comparing
pralatrexate with erlotinib in current and former smokers with advanced
NSCLC after failure of platinum-based therapy. Pralatrexate (FOLOTYN®),
a folate analog targeting dihydrofolate reductase, received accelerated ap-
proval for relapsed/refractory peripheral T-cell lymphoma and has shown
activity in earlier studies in NSCLC. A phase 1 trial in heavily pretreated
patients (pts) with advanced NSCLC reported a 10% ORR, including 2 pts
with durable complete response (26 and 21 months) [Azzoli, ESMO
2009]. Erlotinib, an EGFR tyrosine kinase inhibitor, is approved for use in
NSCLC.
Materials/Methods: Pts who progressed after1 prior platinum-based therapy
with stage IIIB/IV NSCLC, ECOG 0-1, and lifetime smoking history of 100
cigarettes were randomized 1:1 to pralatrexate or erlotinib. Pralatrexate was
administered at 190 mg/m2 (230 mg/m2 initially) IV on days 1 and 15 of a
28-day cycle, and erlotinib 150 mg/day PO. The primary objective was to
estimate overall survival (OS) of pralatrexate vs erlotinib in prespecified sub-
groups. Secondary objectives included PFS, ORR, and safety.
Results: Baseline characteristics for the 201 pts enrolled were balanced
except for histology; 29% vs 47% had squamous carcinoma and 61% vs 46%
had nonsquamous carcinoma in the pralatrexate and erlotinib arms, respec-
tively. Approximately two-thirds of pts in both arms had 1 prior therapy for
NSCLC and 15% of pts had received prior pemetrexed. Efficacy: Pralatrex-
ate OS benefit trend was greatest in pts with nonsquamous histology (n107;
HR0.65), 1 prior therapy (n72; HR0.63), and pts who were light
smokers (n37; HR0.63). The activity of pralatrexate was comparable to
erlotinib in pts with squamous cell carcinoma (HR 1.06). The median PFS
was 3.4 vs 2.8 months in the pralatrexate and erlotinib arms, respectively
(HR  0.91). Safety: Grade 0 mucositis was required for retreatment and
only 1 dose reduction was allowed for AE. Twenty-one percent of pts on the
pralatrexate arm discontinued due to mucositis with most discontinuations
occurring in cycle 1. Analysis of pts who remained on treatment at 30 days
showed an OS benefit trend favoring pralatrexate (HR 0.62).
Conclusions: Several pt groups with advanced NSCLC showed trends for
greater benefit from pralatrexate compared to erlotinib and the results of
PDX-012 support initiation of phase 3 studies. Employment of individual-
ized dose adaptation strategies and a prospective mucositis management plan
to maximize the benefit and tolerability of pralatrexate will be an important
factor to success in pivotal trials.
Author Disclosure Block: K. Kelly: C. Other Research Support; Allos
Therapuetics, Inc.. F. Consulting/Advisory Board; Genentech, Inc. C.G.
Azzoli: C. Other Research Support; Allos Therapeutics, Inc., Genentech
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LBOA3
Molecular Analysis Identifies A Subset Of Non-small Cell Lung
Cancer Patients With Differential Sensitivity To Histone
Deacetylase Inhibitor (hdaci) / Epidermal Growth Factor Re-
ceptor Tyrosine Kinase Inhibitor (egfr-tki) Treatment
R. M. Jotte1, S. E. Witta2, A. I. Spira3, M. A. Neubauer4, K. Konduri5, R. L.
Ruxer6, F. R. Hirsch7, 1Rocky Mountain Cancer Center, Denver, CO,
2Mountain Blue Cancer Care Center, Wheat Ridge, CO, 3Virginia Cancer
Specialists, INOVA Thoracic Oncology Program, Fairfax, VA, 4Kansas City
Cancer Center, Overland Park, KS, 5Baylor-Sammons Cancer Center, Dal-
las, TX, 6Southwest Ft. Worth Cancer Center, Ft. Worth, TX, 7University of
Colorado Cancer Center, Aurora, CO
Purpose/Objective(s): Preclinical data indicate that HDACi combined with
EGFR-TKI can overcome resistance to EGFR-TKI that is linked to epige-
netic changes and the epithelial-mesenchymal transition state of the tumor.
ENCORE-401 (NCT00602030), a randomized, placebo controlled phase 2
clinical trial was conducted with the HDACi entinostat in combination with
the EGFR-TKI erlotinib. Exploratory analysis of biomarkers linked to
clinical outcome was performed to identify patient subsets that may have
greater sensitivity to HDACi/EGFR-TKI combined inhibition.
Materials/Methods: Patients with previously treated stage IIIB/IV NSCLC,
no-prior EGFR-TKIs and, PS 2 were randomized (1:1) to erlotinib 150 mg
PO QD days 1-28 plus entinostat 10mg PO days 1 and 15 Q 28 days (EE) or
erlotinib plus placebo (EP). Primary endpoints included 4 month PFS rate
and OS. Exploratory analyses on archival tissue available for biomarker
assessment included EGFR- and KRAS mutation analyses, EGFR copy
number, and E-cadherin levels.
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Results: 132 patients were randomized (67 EE/65 EP). Study demonstrated
the EE combination had an acceptable safety profile with an outcome
comparable to EP as measured by PFS (median EE 2.3 vs EP 1.9 mo;
HR1.07) or OS (EE 8.9 vs EP 6.7 mos; HR0.91). For EGFR mutation
analysis, 69 samples (52%) were evaluable with 6 (9%) positive for a
sensitizing mutation. For KRAS, 77 samples (58%) were evaluable with 11
(14%) positive for the KRAS mutation. For E-cadherin IHC, 59 samples
(45%) were evaluable and scored as 0-300 (% positive * intensity) with a
pooled median score of 150. Cohorts were defined as hi ( 150; n26) or
low ( 150; n33). The E-cad-hi cohort responded significantly better to EE
treatment as measured by OS (EE median 9.2 (n13) vs EP 4.2 (n13) mo;
HR0.46, p0.08) and a trend towards improved PFS (EE median 3.6 vs EP
1.8 mo; HR0.56, p0.20).
Conclusions: High E-cadherin expression levels at time of diagnosis may
indicate a heightened sensitivity to combined HDACi/EGFR-TKI inhibition.
Given the safety and tolerability of the entinostat/erlotinib treatment, these
promising findings provide the basis for a biomarker driven confirmatory plan.
Author Disclosure Block: R.M. Jotte: None. S.E. Witta: None. A.I. Spira:
None. M.A. Neubauer: None. K. Konduri: None. R.L. Ruxer: None. F.R.
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A Phase II Study Of The Hsp90 Inhibitor STA-9090 Adminis-
tered To Patients With Advanced Non-small Cell Lung Cancer
(NSCLC)
J. Goldman1, E. H. Paschold2, T. Webb3, L. Chen4, M. Kozcywas5, J. M.
Lufkin6, V. Vukovic6, G. I. Shapiro7, M. A. Socinski8, 1Premiere Oncology,
Santa Monica, CA, 2Piedmont Hematology Oncology Associates, PLLC,
Winston-Salem, NC, 3Genesis Cancer Center, Hot Springs, AR, 4Nevada
Cancer Institute, Las Vegas, NV, 5City of Hope, Duarte, CA, 6Synta Phar-
maceuticals, Lexington, MA, 7Dana Farber Cancer Institute, Boston, MA,
8University of North Carolina, Chapel Hill, NC
Purpose/Objective(s): STA-9090 is a potent, second generation, non-
geldanamycin small molecule Hsp90 inhibitor that has shown activity in a
broad range of solid and hematologic cancer models, including models
highly resistant to treatment. The chemical structure of STA-9090 is unre-
lated to the first generation, ansamycin family of Hsp90 inhibitors (e.g.,
17-AAG or IPI-504). Preclinical data support evaluation of Hsp90 inhibitors
in multiple NSCLC subsets driven by a variety of mutant oncogenic proteins.
Materials/Methods: In this open-label, multi-cohort trial, patients with
advanced (stage IIIB or IV) NSCLC receive 200 mg/m2 STA-9090 as a 1-hr
infusion once weekly for 3 consecutive weeks of a 28-day cycle. Patient
cohorts are defined by tumor mutational status: A) EGFR mutation B) KRAS
mutation and C) EGFR and KRAS wild type. Stage 1 of this study consists
of 14 patients enrolled into each of 3 cohorts. Potential predictive genotypic
markers of activity such as EGFR mutation, KRAS mutation, BRAF muta-
tion, PIK3CA mutation or amplification, ERBB2 mutation or amplification,
MET amplification and EML4-ALK translocation will be analyzed. Efficacy
evaluations are performed every 8 weeks. If  2/14 patients within a cohort
have at least SD at 16 weeks of treatment, 9 additional patients will be
enrolled in that cohort (for a total of 23 patients per cohort).
Results: As of 30 September 2010, 65 patients have received STA-9090
(49% M, 51% F, median age 61, range 28-79). The safety profile of
STA-9090 is similar to that observed in Phase 1 studies. The most frequent
AEs reported were diarrhea (66%), nausea (34%) and fatigue (28%). Most
AEs were transient and mild to moderate in severity. Cohort expansion
criteria have been met so far for Cohort C. In order to robustly evaluate the
activity of STA-9090 against tumors with a variety of genetic profiles, the
study has been amended to include an additional 35 patients. Preliminary
genotyping and clinical efficacy data from Cohort C patients will be pre-
sented at the meeting.
Conclusions: Preliminary data analysis indicates STA-9090 has been well
tolerated by NSCLC patients receiving 200 mg/m2 given once weekly for 3
weeks during a 4 week cycle. Preliminary results in previously treated
patients with tumors harboring wild type EGFR and KRAS warrant expan-
sion of this cohort to confirm and further characterize the clinical activity in
this patient subgroup.
Author Disclosure Block: J. Goldman: None. E.H. Paschold: None. T.
Webb: None. L. Chen: None. M. Kozcywas: None. J.M. Lufkin: A.
Employment; Synta Pharmaceuticals. V. Vukovic: Synta Pharmaceuticals.
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Erlotinib versus docetaxel or pemetrexed as second-line therapy
in patients with advanced non-small-cell lung cancer (NSCLC)
and poor prognosis: efficacy and safety results from the phase
III TITAN study
T. Ciuleanu1, L. Stelmakh2, S. Cicenas3, E. Esteban4, on behalf of the TITAN
investigators, 1Institute of Oncology Ion Chiricuta, Cluj-Napoca, Romania;
2Pavlov State Medical University, St Petersburg, Russia, 3Institute of Oncology,
Vilnius Hospital, Vilnius, Lithuania, 4Hospital General de Asturias, Oviedo,
Spain
Purpose/Objectives(s): Patients with advanced NSCLC have few treatment
options after progressing on first-line platinum doublet chemotherapy (PDC).
The three main treatments used in the second-line setting are erlotinib (E),
docetaxel (D) and pemetrexed (P), but head-to-head data from large clinical
trials have been lacking. This international, multicentre, open-label, phase III
study was designed to directly compare the efficacy and safety of E vs
chemotherapy (D or P) in second-line NSCLC following rapid progression
on first-line PDC.
Methods/Materials: A total of 2590 chemonaı¨ve patients with advanced
NSCLC entered the initiation phase and received up to 4 cycles of first-line
PDC. At this point, patients with controlled disease were offered entry into
the SATURN phase III study of erlotinib maintenance, while those with
disease progression were offered entry into TITAN (n424). Within TITAN,
patients were randomized (1:1) to receive E 150mg/d or chemotherapy
(either D or P, at investigators’ discretion; standard regimens), until unac-
ceptable toxicity or progression. Stratification was by stage, ECOG PS,
smoking history and region. The primary endpoint was overall survival (OS)
and secondary endpoints included progression-free survival (PFS), response
rate, biomarker analyses and safety.
Results: The full analysis population comprised 203 patients for E and 221
for chemotherapy (116 for D and 105 for P); baseline characteristics were
balanced between the E and chemotherapy arms. No difference in OS was
observed between arms: HR0.96 (95% CI 0.78–1.19; log-rank p0.73;
median 5.3 months with E vs 5.5 months with chemotherapy). PFS was also
similar across both arms: HR1.19 (95% CI 0.97–1.46; log-rank p0.09;
median 6.3 weeks with E vs 8.6 weeks with chemotherapy). Subgroup
analyses of survival will be presented. Response rate was 7.9% with E vs
6.3% with chemotherapy. Although E was associated with a higher incidence
of treatment-related adverse events (AEs; 58.2% vs 40.8% in the chemo-
therapy arm), most of these were grade 1/2 rash and diarrhoea. Only 1.5% of
patients had an AE leading to death with E vs 5.2% of patients in the
chemotherapy arm. Serious treatment-related AEs were reported in 1% of
patients in the E arm and 6.6% of those in the chemotherapy arm, while
treatment-related AEs leading to withdrawal were seen in 1% and 3.8% of
patients, respectively.
Conclusions: Erlotinib, docetaxel and pemetrexed had similar efficacy as
second-line therapy in patients with advanced NSCLC who progressed
rapidly on first-line PDC, with no significant difference in efficacy observed
between treatments. Erlotinib was well tolerated compared with docetaxel
and pemetrexed in this population.
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LBOA6
Erionite Exposure in North Dakota is Comparable to That
Found in Turkish Villages Which Experience a High Incidence
of Mesothelioma
M. Carbone1, Y.I. Baris2, P. Bertino1, B. Brass3, U. Dogan4, S. Emri2, G.
Gaudino1, M. Gultekin5, S. Jube1, S. Kanodia1, J. Lockey6, C.R. Partridge3,
C. Rinaudo7, Z. Rivera1,8, P.H. Ryan6, M.A. Sens9, I. Steele10, M. Tuncer2,5,
S. Way3, H. Yang1,11, A. Miller12, 1University of Hawaii Cancer Center,
University of Hawaii, Honolulu, HI, 2Hacettepe University, Ankara, Turkey,
3USEPA, Denver, CO, 4University of Iowa, Iowa City, IA, 5Turkish Ministry
of Health, Ankara, Turkey, 6University of Cincinnati, Cincinnati, OH, 7Uni-
versita del Piemonte Orientale, Alessandria, Italy, 8Department of Molecu-
lar Biosciences & Bioengineering, University of Hawaii, Honolulu, HI,
9University of North Dakota, Grand Forks, ND, 10University of Chicago,
Chicago, IL, 11John A. Burns School of Medicine, University of Hawaii,
Honolulu, HI, 12NIEHS, Bethesda, MD
Disclaimer: The views are of the authors and do not necessarily represent the
policies and positions of the NIST, USEPA and NIEHS. Supported in part by
NCI PO-1 114047 to M.C.
Purpose/Objectives(s): Exposure to fibrous erionite causes unprecedented
rates of malignant mesothelioma (MM) mortality (up to 42% of all deaths)
in Turkish villages (Karain, Sarihidir, Tuzkoy, Boyali). Erionite deposits are
present in many US states, including California, Oregon, North and South
Dakota, Arizona and Nevada. In North Dakota (ND), we discovered that over
the past 2–3 decades, more than 300 miles of roads, including school bus
routes, were paved with erionite-contaminated gravel. To determine the
potential health implications of exposure, we compared exposures in the
Turkish villages with elevated MM mortality to exposures associated with
the use of erionite-containing gravel roads in ND.
Methods/Materials: The study evaluated air samples, examined erionite
microchemistry and morphology by transmission electron microscopy and
energy dispersive x-ray spectroscopy, examined TNF-alpha and HMGB1
release from mesothelial cells in vitro, and compared carcinogenicity in vivo.
Radiology was used to evaluate chest changes among 15 ND residents with
a high potential exposure to erionite-containing road gravel.
Results: Exposures measured in ND along erionite-contaminated roadsides,
indoors and inside vehicles, including school buses, equaled or exceeded erionite
exposures in Boyali, where 6.2% of all deaths are caused by MM, although they
were lower than those found in Turkish villages with MM related mortality
ranging from 20–42% of all deaths. The physical and chemical properties of
erionite from Turkish villages and ND are similar. In tissue culture, ND and
Turkish erionite induce HMGB1 and TNF-alpha release from human mesothe-
lial cells and macrophages, and cause malignant transformation of mesothelial
cells. In mice, ND and Turkish erionite caused HMGB1 and TNF-alpha release
and chronic inflammation of the peritoneum and pleura, a process that over time
has been linked to MM. Exposure to erionite-containing road gravel in ND can
result in pleural changes commonly seen with asbestos exposure. Data will be
presented in support of these observations.
Conclusions: Based upon the results of our study and considering the known
latency period, there is concern for increased risk of MM in ND in the future.
Additional investigation and precautionary measures should be undertaken to
reduce exposure to erionite that is occurring in ND andmay be occurring in areas
of the US where large deposits of erionite are present if disturbed. Our findings
provide an opportunity to implement novel preventive and early detection
programs in the US, similar to what we have been doing in Turkey.
Author Disclosure: M. Carbone: None. Y.I. Baris: None. P. Bertino:
None. B. Brass: None. U. Dogan: None. S. Emri: None. G. Gaudino: None.
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Surgery in Patients with Advanced NSCLC following Induction
Polychemotherapy
I. S. Poliakov, V. A. Porhanov, A. L. Kovalenko, V. B. Kononenko, Regional
Hospital # 1, Krasnodar, Russian Federation
Purpose/Objective(s): About 80% patients with primarily diagnosed
NSCLC have non-surgical stages and they are administered drug or radio-
therapy. polychemotherapy. Such administration improves surgical results in
patients with advanced NSCLC.
Materials/Methods: From January 2003 to January 2008, 31 patients with
NSCLC have been referred for neoadjuvant (induction) therapy, of those, 14
patients had advanced unresectable tumor - T4 ( 5 carinal invasions, 3 SVC
invasions, 4 apical lung cancers, 2 tumors attached lobar bronchus, but
pneumonectomy was contraindicated), other 17 patients had multiple medi-
astinal LN invasion (N2-3). Morphological diagnosis was established before
treatment by means of transthoracic biopsy, fiber-optic bronchoscopy,
VATS, videomediastinoscopy. Functional status corresponds to ECOG 0-2.
Re-staging was performed following induction therapy. Six patients (42%) in
the group T4 showed benefitial treatment and they were transferred to the
operable stage.
Results: We performed 2 pneumonectomy with carinal resection, in 1 case -
carinal resection and SVC plasty, 1 pneumonectomy, 1 resection of the upper
lobe with bronchoplasty. Of 17 patients with N2-3, 5 patients (29%) showed
favorable effect, they underwent various volume operations. Postoperative
complication rate was 9%, there was no mortality cases. Survival in operated
and non-operated patients was 23 and 7 months, respectively.
Conclusions: Practical application of induction therapy with treatment
results assessment has allowed to expand possibilities of combined treatment
for NSCLC and re-stage non-resectable tumors, down-stage and improve the
outcomes.
Author Disclosure Block: I.S. Poliakov: None. V.A. Porhanov: None.
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LBPV2
Simultaneous Lung Cancer Resections and Cardiac Surgery via
Sternotomy with Cardiopulmonary Bypass
V. A. Porhanov, I. S. Poliakov, K. O. Barbukhatti, A. A. Scopets, Regional
Hospital # 1, Krasnodar, Russian Federation
Purpose/Objective(s): We observed an increased number of cases with
combined lung cancer and coronary heart disease (CHD) due to common risk
factors - age, smoking and improper pattern of life.
Materials/Methods: Since December 2002 and till December 2009, 112
patients have underwent simultaneous pulmonary and cardiac operations as
they required to be operated on for chest wall, esophagus and heart lesions.
Of those patients in 89 cases (79,4%) we performed simultaneous operations
via sternotomy. In others, in 18 cases (16%) we carried out transcutaneous
angioplasty prior to pulmonary resections, 2 patients (1,8%) underwent
myocardial revascularization on a beating heart via a lateral thoracotomy,
and in 3 cases (2,8%) we performed first cardiac and then pulmonary surgery.
Special feature of those simultaneous operations was surgery performance
during the same anesthesia without cardiopulmonary bypass arrest.
Results: Lobectomies were most common operations, totally 91% of all
resections, and 54% of those were right-sided lobectomies. There were 7
bronchoplastic operations: lobectomies with circular bronchial resections. In
6 cases (86%) it was upper lobectomy and only in one case - lower
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